·986·中华神经科杂志2020年12月第53卷第12期ChinJNeurol,December2020,Vol.53,No.12
[37]CabreiraV,Soares‐da‐SilvaP,MassanoJ.ContemporaryMovDisord,2015,30(2):121‐127.DOI:10.1002/
optionsforthemanagementofmotorcomplicationsinmds.26016.
Parkinson′sdisease:updatedclinicalreview[J].Drugs,[53]WeintraubD,MamikonyanE.Impulsecontroldisorders
2019,79(6):593‐608.DOI:10.1007/s40265‐019‐01098‐w.inParkinson′sdisease[J].AmJPsychiatry,2019,176(1):
[38]StocchiF,GiorgiL,HunterB,etal.PREPARED:5‐11.DOI:10.1176/appi.ajp.2018.18040465.
comparisonofprolongedandimmediaterelease[54]VargasAP,CardosoFEC.Impulsecontrolandrelated
ropiniroleinadvancedParkinson′sdisease[J].MovdisordersinParkinson′sdisease[J].ArqNeuropsiquiatr,
Disord,2011,26(7):1259‐1265.DOI:10.1002/mds.23498.2018,76(6):399‐410.DOI:10.1590/0004‐282X20180052.
[39]FabbriM,RosaMM,FerreiraJJ.Adjunctivetherapiesin[55]AarslandD,CreeseB,PolitisM,etal.Cognitivedeclinein
Parkinson′sdisease:howtochoosethebesttreatmentParkinsondisease[J].NatRevNeurol,2017,13(4):
strategyapproach[J].DrugsAging,2018,35(12):217‐231.DOI:10.1038/nrneurol.2017.27.
1041‐1054.DOI:10.1007/s40266‐018‐0599‐2.[56]中国帕金森病脑深部刺激疗法专家组.中国帕金森病脑
[40]PilleriM,AntoniniA.Therapeuticstrategiestoprevent深部刺激疗法专家共识[J].中华神经科杂志,2012,45(7):
andmanagedyskinesiasinParkinson′sdisease[J].Expert541‐543.DOI:10.3760/cma.j.issn.1006‐7876.2012.07.023.
OpinDrugSaf,2015,14(2):281‐294.DOI:10.1517/ChineseExpertGrouponDeepBrainStimulationTherapy
14740338.2015.988137.forParkinson′sDisease.ConsensusofChineseexpertson
[41]SeppiK,RayChaudhuriK,CoelhoM,etal.UpdateondeepbrainstimulationtherapyforParkinson′sDisease[J].
treatmentsfornonmotorsymptomsofParkinson′sChinJNeurol,2012,45(7):541‐543.DOI:10.3760/cma.j.
disease‐anevidence‐basedmedicinereview[J].Movissn.1006‐7876.2012.07.023.
Disord,2019,34(2):180‐198.DOI:10.1002/mds.27602.[57]中华医学会神经外科学分会功能神经外科学组,中华医学
[42]LiuCF,WangT,ZhanSQ,etal.Management会神经病学分会帕金森病及运动障碍学组,中国医师协会
recommendationsonsleepdisturbanceofpatientswith神经内科医师分会帕金森病及运动障碍学组,等.中国帕
Parkinson′sdisease[J].ChinMedJ,2018,131(24):金森病脑深部电刺激疗法专家共识(第二版)[J].中华神经
2976‐2985.DOI:10.4103/0366‐6999.247210.外科杂志,2020,36(4):325‐337.DOI:10.3760/cma.j.
[43]BaroneP,AmboniM,VitaleC,etal.Treatmentofcn112050‐20200217‐00062.
nocturnaldisturbancesandexcessivedaytimesleepinessChineseSocietyofFunctionalNeurosurgery,Chinese
inParkinson′sdisease[J].Neurology,2004,63(8Suppl3):SocietyofParkinson′sDiseaseandMovementDisorders,
S35‐38.DOI:10.1212/wnl.63.8_suppl_3.s35.Parkinson′sdiseaseandMovementDisorderSectionof
[44]TortiM,BraviD,VaccaL,etal.ArealldopamineagonistsNeurologybranchofChineseMedicalDoctorAssociation,
essentiallythesame?[J].Drugs,2019,79(7):693‐703.DOI:etal.Expertconsensusondeepbrainstimulationtherapy
10.1007/s40265‐019‐01103‐2.forParkinson′sdiseaseinChina(secondedition)[J].ChinJ
[45]WinkelmannJ,AllenRP,H?glB,etal.TreatmentofNeurosurg,2020,36(4):325‐337.DOI:10.3760/cma.j.
restlesslegssyndrome:Evidence‐basedreviewandcn112050‐20200217‐00062.
§
implicationsforclinicalpractice(Revised2017)[J].Mov[58]BloemBR,deVriesNM,EbersbachG.Non‐pharmacological
Disord,2018,33(7):1077‐1091.DOI:10.1002/mds.27260.treatmentsforpatientswithParkinson′sdisease[J].Mov
[46]JostWH,BuhmannC.ThechallengeofpainintheDisord,2015,30(11):1504‐1520.DOI:10.1002/mds.26363.
pharmacologicalmanagementofParkinson′sdisease[J].[59]KoychevI,OkaiD.Cognitive‐behaviouraltherapyfor
ExpertOpinPharmacother,2019,20(15):1847‐1854.non‐motorsymptomsofParkinson′sdisease:aclinical
DOI:10.1080/14656566.2019.1639672.review[J].EvidBasedMentHealth,2017,20(1):15‐20.
[47]RukavinaK,LetaV,SportelliC,etal.PaininParkinson′sDOI:10.1136/eb‐2016‐102574.
disease:newconceptsinpathogenesisandtreatment[J].[60]MorgenthalerT,KramerM,AlessiC,etal.Practice
CurOpinNeurol,2019,32(4):579‐588.DOI:10.1097/parametersforthepsychologicalandbehavioral
WCO.0000000000000711.treatmentofinsomnia:anupdate.AnAmericanAcademy
[48]SchneiderRB,IourinetsJ,RichardIH.Parkinson′sdiseaseofSleepMedicineReport[J].Sleep,2006,29(11):1415‐
psychosis:presentation,diagnosisandmanagement[J].1419.
NeurodegenerDisManag,2017,7(6):365‐376.DOI:[61]VaccaVM.Parkinsondisease:enhancenursingknowledge
10.2217/nmt‐2017‐0028.[J].Nursing,2019,49(11):24‐32.DOI:10.1097/01.
[49]GoodarziZ,MrklasKJ,RobertsDJ,etal.DetectingNURSE.0000585896.59743.21.
depressioninParkinsondisease:asystematicreviewand[62]ZhanA,MohanS,TarolliC,etal.Usingsmartphonesand
meta‐analysis[J].Neurology,2016,87(4):426‐437.DOI:machinelearningtoquantifyParkinsondiseaseseverity:
10.1212/WNL.0000000000002898.theMobileParkinsonDiseaseScore[J].JAMANeurol,
[50]BroenMP,NarayenNE,KuijfML,etal.Prevalenceof2018,75(7):876‐880.DOI:10.1001/jamaneurol.2018.0809.
anxietyinParkinson′sdisease:asystematicreviewand[63]EkkerMS,JanssenS,NonnekesJ,etal.
meta‐analysis[J].MovDis,2016,31(8):1125‐1133.DOI:NeurorehabilitationforParkinson′sdisease:future
10.1002/mds.26643.perspectivesforbehaviouraladaptation[J].Parkinsonism
[51]LizarragaKJ,FoxSH,StrafellaAP,etal.Hallucinations,RelatDisord,2016,22Suppl1:S73‐77.DOI:10.1016/j.
delusionsandimpulsecontroldisordersinParkinsonparkreldis.2015.08.031.
disease[J].ClinGeriatrMed,2020,36(1):105‐118.DOI:[64]SchneiderRB,BiglanKM.Thepromiseoftelemedicinefor
10.1016/j.cger.2019.09.004.chronicneurologicaldisorders:theexampleof
[52]WeintraubD,DavidAS,EvansAH,etal.ClinicalspectrumParkinson′sdisease[J].LancetNeurol,2017,16(7):
ofimpulsecontroldisordersinParkinson′sdisease[J].541‐551.DOI:10.1016/S1474‐4422(17)30167‐9. |
|
